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Singapore (n=9), Hong Kong (n=6), Thailand (n=6), South Korea (n=6), India (n=5), 
Bangladesh (n=1), and Iran (n=1) (some studies pertain to more than one 
country). The CUAs contained 294 ICERs and 436 utility weights. The median 
ICER for all Asian CUAs was $11,000/QALY. The median ICER for tertiary 
prevention interventions ($9,800/QALY, n=157) was favorable, compared to the 
ICERs for primary and secondary prevention interventions ($22,000/QALY, n=69 
and $33,000/QALY, n=62); (p<0.005). The median ICER for immunizations was 
most favorable ($2,300/QALY, n=33), followed by surgical interventions, 
diagnostic interventions and pharmaceuticals and medical devices. In contrast, 
screening programs reported the least favorable ratios ($37,000/QALY, n=90). 
Studies examining infectious diseases had a lower median ICER ($8,500/QALY, 
n=43), compared to ICERs for interventions for cardiovascular diseases and 
cancer. CONCLUSIONS: Over 100 English-language CUAs targeted toward Asian 
countries have been published in English-language journals in recent years. 
Compared to interventions for primary and secondary prevention, interventions 
targeted towards treatments were relatively cost-effective. ICERs for screening 
programs have been relatively cost-ineffective.  
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OBJECTIVES: To evaluate the quality of published cost-effectiveness analyses of 
biologic disease modifying antirheumatic drugs (bDMARDs) for rheumatoid 
arthritis (RA), and to identify methodological issues that can explain the 
discrepancies in the findings of these cost-effectiveness analyses. METHODS: We 
performed a systematic literature review to identify cost-effectiveness analyses 
of biologics indicated for RA. We compared the incremental the cost-
effectiveness ratios (ICERs), the net health benefits (NHB), the net monitory 
benefits (NMB), cost-effectiveness acceptability curves (CEACs), and cost-
effectiveness frontiers. RESULTS: We observed large discrepancies, which were 
predominantly due to the use of different information sources on the 
effectiveness of the considered biologics. First, substantial differences were 
observed in the ICER, NHB, NMB estimates. When considering the uncertainty 
associated with the NHB and NMB estimates, i.e. their 95% confidence intervals, 
differences were still apparent. CEACs and cost-effectiveness frontiers were only 
reported in a sub-set of the identified publications. Reading from the CEACs and 
cost-effective frontier graphs, fixed willingness to pay thresholds yielded 
different probabilities of the considered biologics being cost-effective. 
CONCLUSIONS: Cost-effectiveness analyses of biologics indicated for RA need to 
carefully consider the source of information used as model inputs. Future cost-
effectiveness analyses need to assess the large number of evidence synthesis 
studies conducted on the relative effectiveness of biologics when determining 
the appropriate model inputs.  
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OBJECTIVES: There is some disagreement in the literature as to whether analysts 
should include all “future” costs or make distinctions between related and 
unrelated medical costs. Most guidelines lack definitive recommendations and 
urge analysts to use discretion or to employ sensitivity analysis to show how 
different approaches influence results. This study evaluated cost methods used 
in the published literature and evaluated the impact on cost-effectiveness of 
including different cost categories. METHODS: Systematic review included cost-
utility analyses from the Tufts CEA Registry published since 2000. We included 
cancer intervention studies where the intervention extended life expectancy. We 
identified specific types of costs included, and whether they varied by study 
characteristics such as cancer type, intervention type, country, perspective, 
conclusions. Further, we estimated alternative incremental cost-effectiveness 
ratios (ICERs) in which the ratio reflected different cost categories, including net 
costs due to study intervention, related medical costs of the treated condition, 
and unrelated medical costs. RESULTS: Of the 59 studies reviewed, none 
included medical costs unrelated to the treated condition, and 14 studies (24%) 
excluded direct medical costs related to the condition but not the evaluated 
intervention. Most studies assumed a health care payer perspective, included 
pharmaceutical interventions and reported ratios below $50,000/QALY. A greater 
proportion of government than industry studies included nonmedical costs. 
Recomputing ICERs by eliminating medical costs not affected by the evaluated 
intervention made 26 additional ratios (68%) cost-saving and 4 more ratios (11%) 
cost-effective. Recomputing ICERs by including unrelated medical costs made 6 
fewer ratios (10%) cost-saving and 4 fewer ratios (7%) cost-effective. 
CONCLUSIONS: Conventional CE methods may implicitly penalize therapies that 
add “expensive” life years for chronically ill patients. Presenting ICERs computed 
with and without disease-attributable costs can help better convey how much 
the treatment itself contributes to overall costs. Inclusion of unrelated medical 
costs affects ICERs less strongly.  
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OBJECTIVES: To determine study quality, estimate quality scoring reliability, and 
assess theorized quality predictors of pharmacoeconomic publications 
evaluating recent new molecular entity and biologic license approvals (NMEs) by 
the Food and Drug Administration (FDA). METHODS: Original 
pharmacoeconomic studies (cost-effectiveness, cost-utility, cost-benefit or cost-
minimization) considering any of 50 NMEs approved in 2008-09 and published on 
or before December 31, 2011 were eligible. MEDLINE and the UK National Health 
Service Economic Evaluation Database were searched. Quality was scored with 
the Quality of Health Economic Studies (QHES) instrument for each publication 
by one primary and two secondary reviewers. Interrater reliability was assessed 
using Pearson correlations of QHES scores. Regression was performed of QHES 
score on study characteristics including number of authors, journal impact factor 
one-year pre-submission, journal type (disease-specific/general clinical/health 
economic), NME FDA review classifications (priority/standard and orphan/non), 
publication timing (pre-/post-NME approval), author(s) having academic 
affiliation (yes/no), advanced modeling PE techniques (yes/no), United States 
study (yes/no), data (primary/secondary), incorporation of quality-adjusted life 
years (yes/no), and conclusion (favorable/unfavorable for NME). RESULTS: The 
literature search yielded 203 search results with 37 publications meeting 
inclusion criteria, encompassing 38% of the 2008-09 NMEs. Averaging all 
reviewers, the QHES score range was 15-92, with a median 70, and mean 
68.4±18.4. The total QHES score was significantly correlated between reviewers 
(R= 0.677). A square transformation was applied to QHES score to correct for a 
negatively skewed distribution. Regression analyses were non-significant for all 
study characteristics, although use of advanced modeling PE techniques 
approached significance (p=0.083). CONCLUSIONS: QHES scores indicated that 
the quality of pharmacoeconomic literature for newly-approved NMEs varies, 
although the 51.3%, 19, highest scoring studies (including and above the median) 
were near or exceeded the 75 point threshold considered “good”. Interrater 
reliability for QHES assessment was fair. Sample size was insufficient to identify 
significant predictors among the variables analyzed.  
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OBJECTIVES: To evaluate the extent and quality of published 
pharmacoeconomics studies based in China. METHODS: A systematic literature 
search was conducted using PubMed, Web of Science, and Google Scholar to 
identify pharmacoeconomics studies conducted in China. The keywords 
included different combinations of the following: health economics, 
pharmacoeconomics, cost-effectiveness, and China. The inclusion criteria for the 
studies were as follows: 1) original research articles; 2) written in English; 3) 
compared a pharmaceutical to another pharmaceutical, treatment modality, or 
no treatment; and 4) conducted in China. The articles were reviewed by two 
independent reviewers using the 100- point Quality of Health Economic Studies 
(QHES) scale for pharmacoeconomic studies and a subjective 10-point scale for 
cost studies. Disagreements were settled by a third researcher. General and 
economic analysis information of the articles was collected. RESULTS: A total of 
19 studies were included. The studies were published in 11 different journals 
between 2006 and 2012 with an average of five authors (SD=2.5). The mean QHES 
scores for the 17 pharmacoeconomic studies was 80.4 (SD=9.9) and the mean 
quality score for the two cost studies was 7.0 (SD=0.7). More than two-thirds of 
the authors resided in China (68.4%) and most of them had a medical 
background (89.5%). Most studies were published in journals based in foreign 
countries (not China) (89.5%) and used modeling as their study design (80.0%). 
Articles published in foreign journals had a higher quality score but the 
difference was not significant (80.5 ± 9.7 vs 69.0 ± 8.5). CONCLUSIONS: China-
based pharmacoeconomics studies written in English are limited, but on average, 
are of good quality. Economic evaluation of pharmaceuticals should be 
encouraged in China because appropriate allocation of health care resources is 
important in a country with large unmet medical needs.  
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OBJECTIVES: The recently made coverage decisions by the UK's NICE, Scotland's 
SMC and the allocation of $1.1 billion for comparative effectiveness research by 
the U.S. are strong indicators of trends in pricing and reimbursement that are 
likely to be observed in the future. To gain an additional insight into these 
trends, we analyzed the cost effectiveness studies for the top twenty highest 
selling drugs (~$90-100B worldwide sales). METHODS: The Top 20 drugs were 
selected based on their worldwide sales. For this analysis, we segmented these 
drugs into categories such as primary care, specialty, small molecules, biologics, 
therapy areas, and availability of generic alternatives. We analyzed the cost 
effectiveness studies that were published in peer-reviewed journals. Searches 
were conducted using generic names of the drugs and the phrase “cost 
effectiveness” in an abstract of the published study. RESULTS: Between 2007-
2012, the number of published studies on “cost effectiveness” has increased by 
more than 32%. There is a large variability in CERs for same drugs for different 
indications, in some cases also varying by biomarkers. Primary care drugs had 
lower and less variable CERs than specialty drugs. Variations also exist in 
methodology used by different groups in modeling cost effectiveness, especially 
for time horizon and comparator. The majority of primary care drugs were 
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modeled for a time horizon of 35-40 years or for a lifetime to demonstrate cost 
effectiveness. CONCLUSIONS: This analysis shows the range, variability, and 
methods used for calculation of ICER values for these high budget impact drugs 
and provides lessons for executives and policy makers.  
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OBJECTIVES: Health economics research is in its infancy in India. This 
systematic literature review aimed to identify, evaluate, and characterize  
the variety, quality, and intent of the health economics and outcomes studies 
being conducted in India. METHODS: Studies published in English language 
between 1999 and 2012 were retrieved from Embase and PubMed databases using 
relevant search strategies. Two researchers independently reviewed studies  
as per Cochrane methodology; information on type of research and outcomes 
were extracted. Quality of reporting was assessed for model-based health 
economic studies using a published 100-point Quality of Health Studies (QHES) 
instrument. Subjective assessment was used for the remaining studies. 
RESULTS: Of 546 studies screened, 132 studies were included in the review. The 
broad study categories were cost-effectiveness analyses ([CEA], 54 studies), cost 
analyses (19 studies), and burden of illness (18 studies). The outcomes evaluated 
in cost studies were direct and indirect costs, and incremental cost-effectiveness 
ratio (ICER), quality-adjusted life years (QALYs), and disability-adjusted life years 
(DALYs). Most studies were conducted from societal perspective. Direct medical 
costs assessed cost of medicines, monitoring costs, consultation and hospital 
charges along with non-medical costs (travel and food for patients and c 
are-givers). Loss of productivity and loss of income of patients and care-givers 
were identified as components of indirect cost. Overall, 33 studies assessed QoL, 
and WHO Quality of Life-BREF (WHOQOL-BREF) was the most commonly  
used instrument in these studies. Quality assessment for modeling studies 
showed that most studies were of high quality (mean [range] QHES score to be 
75.5 [34-93]). CONCLUSIONS: This review identified various patterns of health 
economic studies in India. Majority of the CEA studies conducted in recent years 
were of high quality. Despite this, utilization of health care resources is 
inappropriate and economic evaluation needs relevance to the context of health 
care in India.  
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OBJECTIVES: Economic evaluations of health technologies have long relied on 
one-way sensitivity analysis (SA) to examine the impact of parameter 
uncertainty on modeling outcomes. Traditionally, this impact has been 
measured and ranked based on absolute changes in the incremental cost-
effectiveness ratio (ICER) across plausible parameter values and presented in a 
tornado diagram. This format does not adequately identify or prioritize 
parameters where the range of uncertainty causes the ICER to change quadrants 
in the cost-effectiveness (CE) plane. However, these quadrant changes, which 
represent fundamental changes to the CE conclusion, are arguably more 
meaningful than changes in the ICER within a quadrant. This research illustrates 
a novel approach to presenting one-way SA results that focuses on identifying 
parameters with the greatest potential to change the overall CE conclusion 
rather than narrowly focusing on changes to the ICER. METHODS: We developed 
a comprehensive algorithm for ranking the parameters varied in a one-way SA. 
Broadly, we first prioritize parameters with the potential to qualitatively change 
the CE conclusion and then rank parameters based on quantitative changes to 
modeling outcomes. Changes to the CE conclusion are identified based on 
quadrant changes in the CE plane, and parameters are categorized as having the 
potential to change the conclusion both positively and negatively, only 
positively, only negatively, or not at all. Within these categories, a secondary 
ranking based on costs and health outcomes is used. Furthermore, visualization 
techniques anchored in the CE plane help assess whether conclusion changes 
are due primarily to changes in health, changes in costs, or both. RESULTS: This 
research demonstrates that the conclusions-based ranking algorithm works in 
more general settings than the traditional tornado diagram format. 
CONCLUSIONS: The conclusions-based approach is a powerful method that 
provides a more complete picture of the impact of parameter uncertainty in 
economic evaluations.  
 
PRM42  
IDENTIFYING ACCURATE PATIENT-BASED HEALTH AND SOCIAL CARE COSTS 
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OBJECTIVES: Acute Medical Units (AMUs) identify individuals requiring in-
patient care and those who can be discharged. However, readmission rates for 
older people in the year following AMU discharge are high. We aimed to identify 
patient-based health and social–care costs of a cohort of older (70+) people 
discharged home from AMU within 72 hours. METHODS: Although resource-use 
data from social and health care sectors in England is available electronically, 
there is little systems-linkage so data were obtained from each sector separately. 
Hospitalisation and social care data were collected retrospectively for 644 
patients for three months post-AMU discharge using patient administration 
systems. In a subset (n=456), further approvals were gained for general practices, 
ambulance services, intermediate and mental health care. Of 118 general 
practices serving our cohort, data were obtained from 48 (250/456 participants). 
Seventeen were not covered by our approvals, and, despite an expert and 
dedicated team, 53 declined access or did not respond. RESULTS: We obtained 
data on hospitalisations for all participants, and “full” costs for 250 participants. 
Mean (95% CI, median, range) total cost for this subgroup was £2006 (1642-2470, 
0, 0-23612). Secondary care constituted 76.2% costs. Contribution from  
other sectors was: primary care (10.9%), ambulance service (0.7%), intermediate 
care (0.1%), mental health care (2.1%) and social care (10.0%) The top 10% 
participants accounted for 50% of overall cost. CONCLUSIONS: This study was 
resource-intensive due to: complex approvals and access requirements; 
geographical dispersion of participants and data sources; different recording 
systems; varying data quality; different care definitions across geographical 
sites; with manual data extraction often required. Care of older people is 
generally moving from secondary care to primary health care and social care, so 
the costs of other sectors will increase in the future. There is clearly a need to 
improve access and system interoperability and streamline methods for 
obtaining these costs.  
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OBJECTIVES: To validate a theoretical method, using a case study of efficiency 
frontier analysis for HIV/AIDS prevention and treatment, for quantifying lower 
and upper limits of the ICER configurated as a slope of the connected lines on  
the efficiency frontier, whose research poster in theory was presented at the 
ISPOR Dublin 2007. METHODS: A validation study was conducted based on the 
evidence published on the Journal of Medical Economics as one of the first 
studies that identified cost-effectiveness variation in efficient frontiers for 
HIV/AIDS prevention and treatment documented in the database, Cost-
Effectiveness Analysis Registry, at Tufts Medical Center in 2002-2007. RESULTS: 
Recognizing that there are two types of efficiency frontier represented with  
a monotonically increasing function of QALY on the Y-axis and Cost on the X-
axis, and also each efficiency frontier is formulated by two regression models: 
log and square-root models, two types of the mathematical formulae of 
derivatives were obtained according to each regression model. The formula of 
derivatives can provide the slope of the tangent on the efficiency frontier curve, 
given an arbitrary value of cost (or QALY). Therefore, we developed the formula 
that can provide lower and upper slopes of the two tangents, given an arbitrary 
ICER slope which is represented by connecting two points on the efficiency 
frontier curve. The examples of calculations conducted were graphically 
illustrated according to each regression model. CONCLUSIONS: Through this 
validation study, we can confirm that an application of our method is 
theoretically and practically feasible to estimate the lower and upper limits of an 
ICER arbitrarily given on the efficiency frontier curve. This approach will provide 
us with more useful information on the question how we could interpret and 
justify the high value of ICER of new technologies such as molecular-targeted 
drugs.  
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OBJECTIVES: Reimbursement to beneficiaries and cost-effectiveness analyses 
depend on the availability of estimates of billed-charge amounts. In the United 
States, no single data source is universally accepted; rather, several vendors 
compile distributions of billed charges. Studies use these estimates 
interchangeably and there is no preferred metric for characterizing differences in 
conducting comparisons. Nonetheless, the conventional wisdom suggests that 
Medicare data tend to underestimate means and other values relative to 
commercial data. This paper investigates the statistical properties of three 
metrics used to characterize relative differences between two sources of values. 
For these metrics, the difference between the tested and reference values is the 
numerator; the denominators are the tested value (Metric #1), the reference 
value (#2), or the average of the two (#3). METHODS: Each metric is described; 
mathematical proofs and simulations demonstrate the types of bias that can be 
introduced. RESULTS: Two simulations of constructed distributions with 
identical means, one with small value differences and the other with large value 
differences, demonstrate that Metrics #1 and #2 would result in opposite 
inferences. Proofs demonstrate that the expected values of Metrics #1, #2, and #3 
respectively, are negative, positive, and zero. The head to head comparison of 
two billed charge benchmarks finds bias present across all three averages 
(simple, weighted by claim count, and weighted by claim dollars), although it is 
most pervasive for the simple average. The sign of the average of Metric #1 is 
consistently negative, while that for Metric #2 is positive and Metric #3 varies. 
CONCLUSIONS: When many observations are aggregated to generate an overall 
average, the choice of metric affects results, often to the point where the choice 
of one methodology or another can generate diametrically opposite conclusions. 
